POSC399 Treatment Effect and Costs of the Complete Therapeutic Pathway in Patients with First-Line Castration-Resistant Prostate Cancer with Either First-Line Docetaxel or Abiraterone Acetate Plus Prednisone

MS Holleman(Erasmus University Rotterdam), CA Uyl‐de Groot(Erasmus University Rotterdam), IM Van Oort(Radboud University Nijmegen), A. Bergman, N. Mehra(Radboud University Nijmegen), A. Van den Bergh(University Medical Center Groningen), R. van Moorselaar, W.R. Gerritsen(Radboud University Nijmegen), Jules Lavalaye(St. Antonius Ziekenhuis), H.M. Westgeest(Amphia Ziekenhuis), AJM van den Eertwegh(Amsterdam University Medical Centers), Ivan Santi, DM Somford(Canisius-Wilhelmina Ziekenhuis), K. Aben(Netherlands Comprehensive Cancer Organisation), MCP Kuppen(Amphia Ziekenhuis), Sammy Huygens(Ghent University Hospital)
Value in Health
January 1, 2022
10.1016/j.jval.2021.11.1300
Cited by 0

Related Papers

Treatment of High-grade Non–muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial “NIMBUS”
|European Urology|2020|132
Clinical Impact of Polymerase Chain Reaction–Based <i>Aspergillus</i> and Azole Resistance Detection in Invasive Aspergillosis: A Prospective Multicenter Study
|Clinical Infectious Diseases|2023|57
Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant
|Clinical Infectious Diseases|2022|50
Diagnostic Value of Microbial Cell-free DNA Sequencing for Suspected Invasive Fungal Infections: A Retrospective Multicenter Cohort Study
|Open Forum Infectious Diseases|2024|29
Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled Trial
|The Journal of Infectious Diseases|2022|27